A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/13/2019
Start Date:November 25, 2014
End Date:April 10, 2020

Use our guide to learn which trials are right for you!

A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer

This three-cohort, multi-stage, randomized, Phase II, multicenter trial will evaluate the
safety and tolerability and estimate the efficacy of cobimetinib plus paclitaxel versus
placebo plus paclitaxel in Cohort I, of cobimetinib plus atezolizumab plus paclitaxel in
Cohort II, and of cobimetinib plus atezolizumab plus nab-paclitaxel in Cohort III in
participants with metastatic or locally advanced, triple-negative adenocarcinoma of the
breast who have not received prior systemic therapy for metastatic breast cancer (MBC).
Participants may continue on study treatment until the development of progressive disease
(PD) or the loss of clinical benefit, unacceptable toxicity, and/or consent withdrawal. The
Cohort I target sample size is 12 participants for the safety run-in stage and approximately
90 participants in the expansion stage. Each of Cohorts II and III will consist of a safety
run-in stage of approximately 15 participants followed by an expansion stage of approximately
15 participants.


Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Histologically confirmed estrogen receptor (ER)-negative, progesterone receptor
(PR)-negative, and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of
the breast with measurable metastatic or locally advanced disease

- Locally advanced disease must not be amenable to resection with curative intent

- Measurable disease, according to RECIST, v1.1

- Adequate hematologic and end organ function

- Agreement to use highly effective contraceptive methods as stated in protocol

Exclusion Criteria:

Disease-Specific Exclusion Criteria

- Known HER2-, ER-positive, or PR-positive breast cancer by local laboratory assessment

- Any prior chemotherapy, hormonal, or targeted therapy, for inoperable locally advanced
or metastatic triple-negative breast cancer (mTNBC)

- Any systemic anticancer therapy within 3 weeks prior to Cycle 1, Day 1

- Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1

- Major surgical procedure, open biopsy, or significant traumatic injury within 30 days
prior to Cycle 1, Day 1 or anticipation of need for major surgical procedure during
the course of the study

- Prior exposure to experimental treatment targeting rapidly accelerated fibrosarcoma
(Raf), MAP kinase/ERK kinase (MEK), or the mitogen-activated protein kinase (MAPK)
pathway

- Brain metastases (symptomatic or nonsymptomatic) that have not been treated
previously, are progressive, or require any type of therapy (e.g., radiation, surgery,
or steroids) to control symptoms from brain metastases within 30 days prior to first
study treatment dose

Cobimetinib-Specific Exclusion Criteria

- History of or evidence of retinal pathology on ophthalmologic examination that is
considered a risk factor for neurosensory retinal detachment/central serous
chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular
degeneration

- Cobimetinib is metabolized by the hepatic cytochrome P3A4 (CYP3A4) enzyme. Drugs
CYP3A4/5 inhibitors and inducers should be avoided

Atezolizumab-Specific Exclusion Criteria (Cohorts II and III Only)

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins

- Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster
ovary cells or any component of the atezolizumab formulation

- History of autoimmune disease

- Prior allogenic stem cell or solid organ transplantation

- History of idiopathic pulmonary fibrosis (including pneumonitis), drug induced
pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic
organizing pneumonia), or evidence of active pneumonitis on screening chest computed
tomography (CT) scan

- Positive test for Human Immunodeficiency Virus (HIV)

- Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg]
or positive hepatitis B virus [HBV] deoxyribonucleic acid [DNA] test at screening) or
hepatitis C

- Active tuberculosis

- Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or
anticipation that such a live, attenuated vaccine will be required during the study

- Prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune
checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated
protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), or anti-programmed death
ligand-1 (anti-PD-L1) therapeutic antibodies

- Treatment with systemic immunostimulatory agents (including but not limited to
interferons or Interlukin-2 [IL-2]) within 4 weeks or five half-lives of the drug
(whichever is shorter) prior to randomization

- Treatment with systemic corticosteroids or other systemic immunosuppressive
medications within 2 weeks prior to randomization, or anticipated requirement for
systemic immunosuppressive medications during the trial

Cardiac Exclusion Criteria

- History of clinically significant cardiac dysfunction

- Corrected QT interval at screening greater than (>) 480 milliseconds (ms) (average of
triplicate screening measurements)

- Left ventricular ejection fraction (LVEF) below the institutional lower limit of
normal or below 50 percent (%), whichever is lower

General Exclusion Criteria

- No other history of or ongoing malignancy that would potentially interfere with the
interpretation of the pharmacodynamic or efficacy assay

- Pregnancy (positive serum pregnancy test) or lactation

- Uncontrolled serious medical or psychiatric illness

- Active infection requiring IV antibiotics on Cycle 1, Day 1

- Participants who have a history of hypersensitivity reactions to paclitaxel or other
drugs formulated in Cremophor® EL (polyoxyethylated castor oil) or to nab-paclitaxel
and any of the excipients
We found this trial at
23
sites
Orange Park, Florida 32073
?
mi
from
Orange Park, FL
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
13001 E. 17th Pl
Aurora, Colorado 80045
303-724-5000
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Bronx, New York 10461
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bronx, New York 10469
?
mi
from
Bronx, NY
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
1 Ingalls Dr
Harvey, Illinois 60426
(708) 333-2300
Ingalls Memorial Hospital As the area's only independent not-for-profit healthcare system, Ingalls has the ability...
?
mi
from
Harvey, IL
Click here to add this to my saved trials
Kansas City, Missouri 64111
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Kogarah, New South Wales 2217
?
mi
from
Kogarah,
Click here to add this to my saved trials
201 Audubon Boulevard
Lafayette, Louisiana 70503
?
mi
from
Lafayette, LA
Click here to add this to my saved trials
701 East 28th Street
Long Beach, California 90806
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Maywood, Illinois 60153
?
mi
from
Maywood, IL
Click here to add this to my saved trials
3663 South Miami Avenue
Miami, Florida 33133
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Newnan, Georgia 30265
?
mi
from
Newnan, GA
Click here to add this to my saved trials
2501 North Orange Avenue
Orlando, Florida 32804
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Pinehurst, North Carolina 28374
?
mi
from
Pinehurst, NC
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Plantation, Florida
?
mi
from
Plantation, FL
Click here to add this to my saved trials
Tacoma, Washington 98405
?
mi
from
Tacoma, WA
Click here to add this to my saved trials